Skip to main content
. 2015 Oct 20;6(38):41307–41323. doi: 10.18632/oncotarget.5846

Figure 2. E7449 potentiates antitumor activity of temozolomide and carboplatin.

Figure 2

A. antitumor effect of E7449 in combination with TMZ in B16-F10 mouse melanoma isografts. Data represent the mean ± StdDev. TMZ was administered orally once daily for 5 days. E7449 was orally administered once daily in combination with TMZ for 5 days and alone for an additional 2 days. *P < 0.05 versus TMZ alone on days 14 and 20, #P < 0.05 versus vehicle control group on day 14 (one-way ANOVA followed by the Dunnett's multiple comparison test). B. relative body weight of animals treated with E7449, TMZ, and E7449 + TMZ combination. Data represent the mean ± SEM. *Body weight loss was observed in all E7449 + TMZ combination treatment groups on day 7. Recovery from body weight loss was observed in all mice upon completion of drug treatment. C. antitumor effect of E7449 in combination with carboplatin in a MX-1 human breast cancer orthotopic model. Data represent the mean ± SEM. Carboplatin was administered as a single intravenous dose at 60 mg/kg on day 3 or 4. E7449 was orally administered once daily at 100 mg/kg with administration beginning on either day 3 or day 4. *P < 0.05 versus E7449 D4 + carboplatin D3 on day 19. D. relative body weights of animals treated with E7449 + carboplatin combination. No significant body weight loss was observed in any animals over the course of the experiment.